Conference Coverage

VIDEO: NCI estimation of MBC numbers a start, but more is needed


 

AT ASCO 2017

– After Shirley A. Mertz, JD, was diagnosed with metastatic breast cancer, she was surprised to learn the government wasn’t counting people like her in data gathered on the disease. Only a minority of women with the disease – those diagnosed de novo – are included in Surveillance, Epidemiology and End Results (SEER) data, she said in a video interview at the annual meeting of the American Society of Clinical Oncology.

A recently published report by a National Cancer Institute mathematician and her associates estimates that about 155,000 women are living with metastatic breast cancer and that three-quarters of those women were initially diagnosed with lower-stage disease that progressed to stage IV. Ms. Mertz, president of the Metastatic Breast Cancer Network, says the estimate is a good start, but it’s important to go further and include those diagnosed with a metastatic recurrence in SEER data to get an accurate view.

“If we are not counted, then it appears we don’t matter, and how can we know if we are doing better if we don’t know how many of us are out there,” she said.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

On Twitter @NikolaidesLaura

Recommended Reading

VIDEO: TRK inhibitor shows 76% ORR across diverse cancers harboring TRK fusions
Breast Cancer ICYMI
VIDEO: Olaparib improves outlook in women with BRCA-related HER2-negative MBC
Breast Cancer ICYMI
Test goes wide and deep to detect free tumor DNA in blood
Breast Cancer ICYMI
Biomarker predicts prolonged depression in breast cancer patients
Breast Cancer ICYMI
Immune-agonist combo has activity against several tumor types
Breast Cancer ICYMI
VIDEO: Survival improves when cancer patients self-report symptoms
Breast Cancer ICYMI
VIDEO: Routine genomic testing identifies actionable alterations in 52% of tumors
Breast Cancer ICYMI
VIDEO: Pertuzumab prolongs disease-free survival in HER2+ early breast cancer
Breast Cancer ICYMI
OlympiAD’s positive results spell good news for olaparib in breast cancer
Breast Cancer ICYMI
VIDEO: Metastatic Trial Search links MBC patients to relevant trials
Breast Cancer ICYMI

Related Articles